Are There Red Flags in the Trial Results?Introduction:Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce sole reliance on Korlym for revenue generation and shift towards a multi-asset profitability company.  If Relacirilant's PDUFA outcome is unfavorable, it would significantly affect Corcept's valuation, since they will have no other pre-registration drug expec ...